120 / 1498
•
Still a role for watch & wait in asymptomatic pts
•
Wait for indication of treatment
•
Combined R-chemo standard; R-CHOP or R-Benda most often used
•
R-Benda with longer PFS and lower toxicity
•
No clear superiority of R-CHOP over R-CVP
•
R-chemo plus R-maintenance current best option in follicular,
particularly in relapsed disease
•
High-dose chemo and ASCT in r&r or transformed pts
•
Perspectives: Bortezomib, Lenalidomide, Obinutuzumab (GA101),
Ofatumumab, Temsirolimus, Ibrutinib, Idelalisib, ABT-199
Standard of care in pts with indolent lymphomas